Related Experiment Video
Updated: Feb 27, 2026
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease
Yasmeen Golzar1, Rami Doukky1,2
1Division of Cardiology, Cook County Health and Hospitals System, Chicago, IL.
Insights
Single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI) aids cardiovascular risk assessment in end-stage renal disease (ESRD) patients. Despite imperfect diagnostic accuracy, SPECT MPI offers valuable prognostic insights for this high-risk population.
Area of Science:
- Cardiology
- Nephrology
- Nuclear Medicine
Background:
- Patients with end-stage renal disease (ESRD) face elevated cardiovascular morbidity and mortality risks.
- Accurate cardiac risk assessment is crucial for ESRD patients, especially those awaiting kidney transplantation.
- Coronary artery disease (CAD) burden is significant in the ESRD population, complicating risk stratification.
Purpose of the Study:
- To review the diagnostic and prognostic performance of single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in ESRD patients.
- To evaluate the clinical value and future directions of SPECT MPI for cardiovascular risk assessment in this population.
- To discuss the challenges and controversies surrounding MPI utilization in ESRD.
Main Methods:
- Literature review focusing on SPECT MPI in ESRD patients.
- Analysis of diagnostic and prognostic performance data.
- Examination of clinical guidelines and novel pharmacological stress agents.
Main Results:
- Stress MPI provides prognostic information beyond clinical data.
- Regadenoson, a novel vasodilator stress agent, is safe and effective in ESRD patients.
- Ancillary findings like heart rate response to stress offer incremental risk stratification.
Conclusions:
- SPECT MPI is a valuable non-invasive tool for cardiovascular risk assessment in ESRD patients.
- Despite limitations in diagnostic accuracy for this population, its prognostic utility is recognized.
- Further research and refined application are needed to optimize its role in ESRD care.
Purpose Of Review:
Patients with end-stage renal disease (ESRD) have an increased risk of cardiovascular morbidity and mortality. Cardiac risk assessment, though challenging, is critical in these high-risk patients, particularly in the pre-transplant population. In this review, we discuss the burden of coronary artery disease in the ESRD population and review the literature on the diagnostic and prognostic performance, clinical value, and future directions of single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in ESRD patients.
Recent Findings:
Stress myocardial perfusion imaging provides incremental prognostic value to clinical data. The AHA/ACCF consensus statement on the cardiac assessment of kidney transplant candidates provides some guidance on the selection of asymptomatic patients for further non-invasive risk stratification. Additionally, the novel selective A2A receptor agonist vasodilator stress agent, regadenoson, is safe and effective in ESRD and has recently been approved by the Food and Drug Administration for use in this population. Ancillary stress MPI findings, namely heart rate response to vasodilator stress, can provide incremental risk stratification.
Summary:
While myocardial perfusion imaging is widely used as a risk assessment tool, its utilization and clinical implications in the ESRD population are controversial. Though stress SPECT-MPI has imperfect diagnostic accuracy in this specific patient population, it is still a valuable non-invasive modality in cardiovascular risk assessment.
